EdiTy Therapeutics
Edity Therapeutics has developed a groundbreaking platform technology that delivers therapeutic proteins with exceptional precision and efficiency. This technology unlocks the potential to modulate previously inaccessible intracellular targets, offering new hope for treating a wide range of diseases. The company is focused on creating immune cell delivery technology to improve patient health by delivering therapeutic proteins directly into diseased cells, especially in the context of cancer and solid tumors. Their approach leverages advanced AI algorithms to engineer proteins and uses immune cells for targeted delivery, opening new avenues for intracellular therapy.
Industries
Nr. of Employees
small (1-50)
EdiTy Therapeutics
10 Menachem Plaut St. 7670609, Rehovot, IL
Products
Immune cell intracellular protein delivery platform
A platform that loads therapeutic proteins into lymphocyte secretory vesicles and uses engineered immune cells to deliver functional proteins into the cytosol of target cells for intracellular modulation.
Immune cell intracellular protein delivery platform
A platform that loads therapeutic proteins into lymphocyte secretory vesicles and uses engineered immune cells to deliver functional proteins into the cytosol of target cells for intracellular modulation.
Services
Collaborative partnerships with pharmaceutical or manufacturing organizations to support therapeutic development and scale.
Collaborative partnerships with pharmaceutical or manufacturing organizations to support therapeutic development and scale.
Expertise Areas
- Intracellular protein delivery
- Cell therapy engineering (T-cell and NK-cell platforms)
- AI-driven protein engineering
- CAR/TCR targeting and activation
Key Technologies
- Immune cell-based intracellular delivery
- Lymphocyte secretory vesicle engineering
- T-cell and NK-cell engineering
- CAR/TCR targeting constructs